Remove Clinic Remove Nuclear Medicine Remove Radiation Remove Radiopharmaceuticals
article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. It causes radiation injury that may be visible as dry desquamation or moist desquamation, for example.

article thumbnail

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Imaging Technology

announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Imaging Technology

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

Extravasation rulemaking to dominate ACMUI public meeting June 17

AuntMinnie

Nuclear medicine injection extravasations and medical events will be the focus of the Advisory Committee on the Medical Uses of Isotopes (ACMUI)'s public teleconference on June 17. Nuclear Regulatory Commission (NRC) rulemaking. That might do away with diagnostic concerns, Flannery noted.